GlassScriptPhysician profile
Tobi Floyd Todd
NPI 1427045319
$1,598.62
in general payments reported to CMS, 2019-2025
25 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $44.10 · 2021: $41.86 · 2023: $723 · 2024: $187 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802 · Travel and Lodging: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.65 |
| Travel and Lodging | $303.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $585.93 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $139.05 | 2023 | Seglentis |
| Trilliant Surgical LLC. | $92.09 | 2019 | |
| Amniox Medical, INC. | $71.01 | 2019 | |
| Depuy Synthes Sales INC. | $59.75 | 2024-2025 | |
| Polymedics Innovations INC. | $58.20 | 2023 | |
| Scilex Pharmaceuticals INC. | $56.72 | 2019 | |
| Convatec INC. | $54.55 | 2023-2025 | |
| Kaleo, INC. | $52.66 | 2019 | |
| Arcutis Biotherapeutics, INC. | $46.46 | 2023 | |
| Nevro Corp. | $45.75 | 2024 | Senza |
| Organogenesis INC. | $41.00 | 2021-2023 | Puraply |
| Smith+Nephew, INC. | $38.57 | 2025 | Na, Healicoil, Footprint |
| Integra Lifesciences Corporation | $37.61 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $33.46 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Osteomed LLC | $31.57 | 2020 | |
| Kerecis Limited | $23.55 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Osiris Therapeutics INC. | $20.64 | 2019 | |
| Averitas Pharma INC. | $19.45 | 2025 | Qutenza |
| Dexcom, INC. | $17.80 | 2024 | Dexcom G6 Transmitter |
| Zimmer Biomet Holdings, INC. | $17.14 | 2021 | |
| Horizon Therapeutics Plc | $16.95 | 2019 | |
| Acell, INC. | $13.41 | 2019 | |
| Merck Sharp & Dohme LLC | $12.77 | 2019 | |
| Paragon 28, INC. | $12.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tobi Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.